Phase I study of combined indomethacin and platinum-based chemotherapy to reduce platinum-induced fatty acids.

Daphne L van der VeldenGeert A CirkelJulia M HouthuijzenE van WerkhovenJeanine M L RoodhartLaura G M DaenenSovann KaingJohan GerritsNanda M Verhoeven-DuifCecile GrootscholtenHenk BootCristisiana SessaHaiko J BloemendalFilip Y De VosEmile E Voest

Published in: Cancer chemotherapy and pharmacology (2018)

Combined indomethacin and CAPOX treatment is safe and reduces the concentrations of 12-S-HHT, which may be associated with improved chemosensitivity. The recommended phase II dose is 75 mg indomethacin TID given 8 days surrounding standard dosed CAPOX.

Keyphrases

phase ii
clinical trial
fatty acid
open label
diabetic rats
high glucose
randomized controlled trial
phase iii
locally advanced
double blind
drug induced
squamous cell carcinoma
placebo controlled
oxidative stress
combination therapy
radiation therapy